분자유전학실험실 (단국대학교 분자생물학과)



 이성욱 ( 2014-11-20 15:30:14 , Hit : 1223
 Gilead wins European approval of next-generation hepatitis C drug




Nov 18, 2014, 10:52am PST
  
John Martin of Gilead


Tony Avelar

John Martin of Gilead
    


          
Ron LeutyReporter-
San Francisco Business Times

Gilead Sciences Inc.'s next-generation hepatitis C drug won European approval Tuesday, opening the door for the drug to be sold in 28 countries.

Pricing of Harvoni, which has raised eyebrows at $95,000 in the United States, is a little more complex since the Foster City-based company (NASDAQ: GILD) must negotiate with individual countries.

Still, Wall Street viewed the approval by the European Commission positively, pushing the stock nearly 3 percent higher to $103.33 per share in mid-day trading, compared to Monday's close. The stock had fallen more than 10 percent this month, through Monday, due to concerns about insurers paying the hefty price.


See Also
Gilead seeks FDA approval for new HIV pill
Gilead's $1,000-a-pill hepatitis C drug may make financial sense for prisons

Harvoni — the first once-daily tablet targeting chronic hepatitis C — was approved last month by the Food and Drug Administration. It combines the drug ledipasvir with Sovaldi, Gilead's first-generation hepatitis C drug that was approved in the United States in December 2013 and in Europe in January 2014.

Gilead Chairman and CEO John Martin and other company executives have argued that three to four months of Harvoni and Sovaldi are valuable because they steer hepatitis C patients away from 48 weeks of injections of interferon and ribavirin, two drugs whose side effects are blamed for patients discontinuing therapy.

Chronic hepatitis C can lead to liver cancer and transplants, and Gilead officials have said that the high, short-term prices of Harvoni and Sovaldi in the United States are less than the longer-term prices of liver cancer drugs and transplantation.

European approval of Harvoni in hepatitis C patients with genotype 1 — the most prevalent form of the disease in Europe — and genotype 4 comes a week after Gilead said Harvoni had cure rates of 96 percent to 97 percent in a study of patients who had cirrhosis and hadn't benefitted from previous treatments.







1087   에볼라 확산원인에 대한 새로운 주장  이성욱 2015/01/06 1189
1086   “Kissing Disease” Virus Promotes Malignant Breast Cancer Development  이성욱 2016/08/03 1189
1085   생명과학 연구에서 암컷쥐가 필요한 이유  이성욱 2015/07/23 1190
1084   융합연구리뷰 | Convergence Research Review  이성욱 2016/01/08 1192
1083   인류의 역사를 고스란히 보여주는 결핵균의 게놈  이성욱 2015/01/21 1201
1082   [바이오토픽] 브로드 연구소, 열띤 CRISPR 특허전쟁에서 승리  이성욱 2017/02/16 1206
1081   유전자치료제 연구개발 및 규제 동향 2015-식품의약품안전처  이성욱 2016/01/20 1209
1080   의문이 제기된 `젊은 피`의 항노화 효과  이성욱 2015/05/22 1210
1079   Cost to Develop a Drug More Than Doubles to $2.56 Billion  이성욱 2014/11/21 1218
1078   FDA approves 9-valent HPV vaccine for certain cancers  이성욱 2014/12/12 1222
1077   정밀의학의 끝: 개인화된 종양백신을 개발하는 과학자들  이성욱 2016/04/26 1222
  Gilead wins European approval of next-generation hepatitis C drug  이성욱 2014/11/20 1223
1075   특허전쟁: 미국 특허청, CRISPR의 특허권 중재 시작  이성욱 2016/03/08 1225
1074   미국 과학·공학·의학 아카데미, 「GM 베이비」의 진행방향에 대한 윤곽 발표  이성욱 2017/02/16 1225
1073   세계 20여 개국 과학자들, 유전자편집 정상회담 개최  이성욱 2015/12/05 1226
1072   CRISPR의 능력을 배가(倍加)시키는 미니 유전자  이성욱 2015/04/02 1233
1071   Janssen, Isis Pharma Ink Up-to-$835M Antisense Agreement  이성욱 2015/01/07 1236
1070   줄기세포로 만든 초기 난자와 정자  이성욱 2014/12/31 1238
1069   맹인을 위한 유전자치료의 쇠퇴  이성욱 2015/05/08 1245
1068   유전자편집치료에 희망을 준 백혈병치료  이성욱 2015/11/11 1246

[1][2][3][4][5][6][7][8][9] 10 ..[64] [다음 10개]
 

Copyright 1999-2024 Zeroboard / skin by ROBIN